Forge Biologics Krabbe Disease Trial
Preliminary clinical data on the treatment of first patient
Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease.
– FBX-101 clinical data demonstrates safety and initial efficacy from the RESKUE trial
– FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180
– FBX-101 significantly increased GALC enzyme activity in leukocytes and patient exhibited improved motor function and normal brain development
To read the full press release: Full Press Release 30.08.22